Evidence map›Paper›PMID 28795363›Full record

ArticleStem cell reviews and reports2017

Fibroblast Growth Factor Type 1 (FGF1)-Overexpressed Adipose-Derived Mesenchaymal Stem Cells (AD-MSC

Hamed Ghazavi, Seyed Javad Hoseini, Alireza Ebrahimzadeh-Bideskan, Baratali Mashkani, Soghra Mehri, Ahmad Ghorbani, Kayvan Sadri, Elahe Mahdipour, Faezeh Ghasemi, Fatemeh Forouzanfar and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Stem cell reviews and reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Treatment of ischemic stroke with modified mesenchymal stem cells.International journal of medical sciences · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Hamed GhazaviDepartment of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Javad HoseiniDepartment of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Alireza Ebrahimzadeh-BideskanDepartment of Anatomy and Cell Biology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Baratali MashkaniDepartment of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Soghra MehriPharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Ahmad GhorbaniPharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.
Kayvan SadriNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Elahe MahdipourDepartment of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Faezeh GhasemiDepartment of Biotechnology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Fatemeh ForouzanfarDepartment of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Azar HoseiniPharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.
Ali Reza PasdarDepartment of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamid Reza SadeghniaDepartment of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. sadeghniahr@mums.ac.ir.
Majid Ghayour-MobarhanDepartment of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. ghayourm@mums.ac.ir.
Mashhad University of Medical Sciences · IRArak University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke, as the second most common cause of death, imposes a great financial burden on both the individual and society. Mesenchymal stem cells from rodents have demonstrated efficacy in experimental animal models of stroke due to enhanced neurological recovery. Since FGF1 (fibroblast growth factor 1) displays neuroprotective properties, for the first time, we investigated the effect of acute intravenous administration of FGF1 gene transfected adipose-derived mesenchymal stem cell (AD-MSC

Indexed as

Mesenchymal Stem Cell TransplantationRecovery of FunctionAdipocytesAdipose TissueAnimalsCell DifferentiationCerebrumDisease Models, AnimalFibroblast Growth Factor 1Gene ExpressionHumansInfarction, Middle Cerebral ArteryInfusions, IntravenousMaleMesenchymal Stem CellsRadiopharmaceuticalsFibroblast Growth Factor 1RadiopharmaceuticalsTechnetium Tc 99m ExametazimeAdipose-derived mesenchymal stem cells (AD-MSC)Fibroblast growth factor 1 (FGF1)StrokeTransfectionTransient middle cerebral artery occlusion (tMCAO)

Identifiers

PMID28795363
OpenAlexW2742187740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.